Results of induction chemotherapy followed by concurrent chemoradiation in unresectable locally advanced non-small lung cancer
- VernacularTitle:诱导化疗加三维适形放疗同步化疗不可手术的局部晚期非小细胞肺癌的疗效分析
- Author:
Wenyong TAN
;
Desheng HU
;
Qibin SONG
;
Hao TANG
;
Liming XU
;
Fanyu ZENG
;
Xiaohong WANG
;
Lai WEI
;
Zhengchao PI
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cel lung/radiotherapy;
Three dimension conformal radiotherapy;
Carcinoma,non-small cel lung/chemotherapy;
Cisoplatin
- From:
Chinese Journal of Radiation Oncology
2008;17(3):184-188
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the toxicity and efficacy of induction chemotherapy followed by concurrent cisplatin chemotherapy and three dimensional conformal radiotherapy (3DCRT) for inoperable locally advanced non-small cell lung cancer (LA-NSCLC). Methods Totally 76 patients with LA-NSCLC received two cycles induction chemotherapy followed by 3DCRT with a median dose of 68 Gy (64 to 74 Gy).During the 3DCRT, cisplatin (25 mg/m2, weekly) was given intravenously for 6-7 times. Results The CR rate, PR rate and overall response rate of induction chemotherapy were 3% ,42% and 45%. After the concurrent chemoradiation, the corresponding figures were 10%, 62% and 72%. The median survival time (MST) and median progression-free survival (PFS) of all patients were 16.6 months and 10.3 months. The 1-, 2- and 3-year overall survival (OS) and PFS rates were 67% , 35% , 21% and 42% , 15%, 6%. Of patients with stage ⅢA and stage ⅢB disease,the MST were 19.7 months and 15.6 months, the PFS were 10.8 months and 9.4 months. The major treatment-related toxicities included radiation esophagitis, radiation pneumonitis, nausea ( or vomiting) and leukopenia. The major pattern of treatment failure was distant metastasis. Forty-five patients (59%) experienced the local recurrence or/and distant metastasis, including 4 (9%) with in-field failure, 38 (84%) distant metastasis and 3 (7%) malignant pleural effusion. Conclusions Induction chemotherapy followed by concurrent weekly cisplatin and 3DCRT for inoperable locally advanced NSCLC results in encouraging outcomes and acceptable tolerance.
